Home › Kanser sa Ovary › Connecticut
Pag-aaral pangklinika para sa Kanser sa Ovary sa Connecticut
28 pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa mga site sa Connecticut.
Mga Lungsod sa Connecticut
- New Haven21 pag-aaral
- East Norwalk10 pag-aaral
- Hartford7 pag-aaral
- Norwalk5 pag-aaral
- Danbury5 pag-aaral
- Stamford5 pag-aaral
- Bridgeport5 pag-aaral
- New London3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- at 8 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07001748A Study of PHST001 in Advanced Solid Tumors
- Yale Cancer Center, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04585750A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06172478Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Yale University - Yale University School of Medicine, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07360314A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Danbury Hospital, Western Connecticut Health Network /ID# 274783, Danbury
- Yale University School of Medicine /ID# 275794, New Haven
- Norwalk Hospital /ID# 274561, Norwalk
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0158 - Hartford HealthCare, Hartford
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT05128825Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, New Haven
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05867251A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07229313A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- UConn Health, Farmington
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213804Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Yale University, Yale Cancer Center, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Yale Cancer Center, New Haven
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06303505A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001), New Haven
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 3, 2026 · NCT06824467Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Danbury Hospital, Danbury
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Set 1, 2026 · NCT07564141A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07182149A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Danbury Hospital, Danbury
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- Hartford Hospital, Hartford
- at 5 pa
Nagre-recruit
Edad 35 hanggang 50 · Kababaihan · Na-update Ago 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Danbury Hospital, Danbury
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- at 8 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06580314A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Yale University School of Medicine, New Haven
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT06161025A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Norwalk Hospital, Norwalk
Nagre-recruitPhase 2
Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
- Yale University, New Haven
Nagre-recruit
Edad 18 pataas · Kababaihan · Na-update Hul 20, 2026 · NCT05761561A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
- Yale University, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Kababaihan · Na-update Hul 6, 2026 · NCT07226427Integrated Cancer Repository for Cancer Research
- Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Yale University, Yale Cancer Center, New Haven
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT06993844Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Hartford Hospital, Hartford
- Smilow Cancer Hospital at Yale- New Haven, New Haven
- Yale University School of Medicine, New Haven
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Abr 16, 2026 · NCT05659381A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Yale University, Yale Cancer Center, New Haven
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- Yale University, New Haven
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 14, 2026 · NCT06234423CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Smilow Cancer Hospital at Yale - New Haven, New Haven
Nagre-recruitPhase 2
Edad 18 pataas · Kababaihan · Na-update Dis 23, 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Hartford
- Massive Bio SYNERGY-AI site, Norwalk
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.